Dezamizumab
Dezamizumab (GSK 2398852) is a fully humanized recombinant monoclonal IgG1 anti-serum amyloid P component (SAP) antibody, with potential anti-amyloid activity. Dezamizumab triggers immunotherapeutic clearance of amyloid. Dezamizumab can be used in research of Amyloid light-chain (AL) amyloidosis[1].
Product Specifications
CAS Number
1662664-56-3
Product Name Alternative
GSK 2398852; Anti-Serum Amyloid P/SAP Reference Antibody (dezamizumab)
UNSPSC
12352203
Target
Others
Type
Inhibitory Antibodies
Related Pathways
Others
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/dezamizumab.html
Purity
99.96
Solubility
10 mM in DMSO
Smiles
[Dezamizumab]
Molecular Weight
(144.18 kDa)
References & Citations
[1]Parrondo RD, et, al. Antibody-based immunotherapy for treatment of immunoglobulin light-chain amyloidosis. Br J Haematol. 2020 Dec;191 (5) :673-681.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
Phase 2
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
